CD8A and neoplasm: Several studies have shown that the decrease in the proliferative and invasive abilities of most tumor cells, including GC, HCC, and BC, as well as the increased functions of immune cells such as CD8+T and NK cells can be observed after using the CD73's enzyme activity inhibitor APCP or anti-CD73 mAb [66, 67].